Dosing guidance for intravenous colistin in critically ill patients

Clinical Infectious Diseases

Volumn 64, Issue 5, 2017, Pages 565-571

  Nation, Roger L ^a   Garonzik, Samira M ^c   Thamlikitkul, Visanu ^e   Giamarellos Bourboulis, Evangelos J ^f   Forrest, Alan ^c   Paterson, David L ^b   Li, Jian ^a   Silveira, Fernanda P ^d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e MAHIDOL UNIVERSITY   (Thailand)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Critically ill patients; Dosing guidance; Influence of renal impairment and renal replacement modalities; Intravenous colistin; Population pharmacokinetics

Indexed keywords

COLISTIN; CREATININE; ANTIINFECTIVE AGENT;

ADULT; AGED; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; CONCENTRATION AT STEADY-STATE; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MULTICENTER STUDY; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PILOT STUDY; PRACTICE GUIDELINE; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PRACTICE GUIDELINES AS TOPIC; RENAL REPLACEMENT THERAPY; YOUNG ADULT;

EID: 85018170251     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw839     Document Type: Article

References (29)

1. Li J, Nation RL, Turnidge JD, et al. Colistin: The re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589-601.
2. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1953-8.
3. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1964; 23:552-74.
4. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
5. Karaiskos I, Friberg LE, Pontikis K, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother 2015; 59:7240-8.
6. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 2015; 70:3291-7.
7. Sorli L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study. BMC Infect Dis 2013; 13:380.
8. Forrest A, Silveira FP, Thamlikitkul V, et al. Toxicodynamics for colistin-associated changes in creatinine clearance. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC.
9. Horcajada JP, Sorli L, Luque S, et al. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Agents 2016; 48:725-7.
10. Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 2016; 62:552-8.
11. Jelliffe R. Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen. Am J Nephrol 2002; 22:320-4.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
13. European Medicines Agency. Annex III: amendments to relevant sections of the summary of product characteristics and the package leaflets. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/Polymyxin-31/WC500176332.pdf. Accessed 11 January 2017.
14. Gregoire N, Mimoz O, Megarbane B, et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rational. Antimicrob Agents Chemother 2014; 58:7324-30.
15. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57:524-31.
16. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014; 59:88-94.
17. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-84.
18. Food and Drug Administration. Coly-Mycin M Parenteral (Colistimethate for Injection, USP). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/050108s030lbl.pdf. Last accessed 11 January 2017.
19. Karvanen M, Plachouras D, Friberg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2013; 57:668-71.
20. Leporati M, Bua RO, Mariano F, et al. Determination by LC-MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit 2014; 36:182-91.
21. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005; 49:4814-5.
22. Marchand S, Frat JP, Petitpas F, et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010; 65:1836-7.
23. Luque S, Sorli L, Li J, et al. Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptible Pseudomonas aeruginosa. J Chemother 2014; 26:122-4.
24. Strunk AK, Schmidt JJ, Baroke E, et al. Single-and multiple-dose pharmacokinetics and total removal of colistin in a patient with acute kidney injury undergoing extended daily dialysis. J Antimicrob Chemother 2014; 69:2008-10.
25. Jitmuang A, Nation RL, Koomanachai P, et al. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. J Antimicrob Chemother 2015; 70:1804-11.
26. Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012; 67:2459-62.
27. Jacobs M, Gregoire N, Megarbane B, et al. Population pharmacokinetics of colistin methanesulphonate (CMS) and colistin in critically ill patients with acute renal failure requiring intermittent haemodialysis. Antimicrob Agents Chemother 2016; 60:1788-93.
28. Mariano F, Leporati M, Carignano P, Stella M, Vincenti M, Biancone L. Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol 2015; 28:623-31.
29. Karaiskos I, Friberg LE, Galani L, et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 2016; 48:337-41.